nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2E1—Dacarbazine—pancreatic cancer	0.0638	0.103	CbGbCtD
Citalopram—CYP2E1—Tamoxifen—pancreatic cancer	0.0508	0.0823	CbGbCtD
Citalopram—CYP2B6—Tamoxifen—pancreatic cancer	0.0501	0.0812	CbGbCtD
Citalopram—CYP2B6—Irinotecan—pancreatic cancer	0.0384	0.0624	CbGbCtD
Citalopram—CYP1A2—Dacarbazine—pancreatic cancer	0.0369	0.0599	CbGbCtD
Citalopram—CYP2C19—Tamoxifen—pancreatic cancer	0.0318	0.0516	CbGbCtD
Citalopram—CYP1A2—Tamoxifen—pancreatic cancer	0.0294	0.0476	CbGbCtD
Citalopram—ABCB1—Tamoxifen—pancreatic cancer	0.0257	0.0416	CbGbCtD
Citalopram—CYP1A2—Erlotinib—pancreatic cancer	0.025	0.0405	CbGbCtD
Citalopram—CYP2D6—Tamoxifen—pancreatic cancer	0.0242	0.0392	CbGbCtD
Citalopram—ABCB1—Gemcitabine—pancreatic cancer	0.0221	0.0359	CbGbCtD
Citalopram—ABCB1—Erlotinib—pancreatic cancer	0.0218	0.0354	CbGbCtD
Citalopram—CYP1A2—Fluorouracil—pancreatic cancer	0.0216	0.0351	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—pancreatic cancer	0.021	0.0341	CbGbCtD
Citalopram—CYP2D6—Erlotinib—pancreatic cancer	0.0206	0.0334	CbGbCtD
Citalopram—ABCB1—Irinotecan—pancreatic cancer	0.0197	0.032	CbGbCtD
Citalopram—CYP3A4—Tamoxifen—pancreatic cancer	0.0154	0.0249	CbGbCtD
Citalopram—ABCB1—Docetaxel—pancreatic cancer	0.0144	0.0234	CbGbCtD
Citalopram—ABCB1—Sunitinib—pancreatic cancer	0.0144	0.0233	CbGbCtD
Citalopram—CYP3A4—Erlotinib—pancreatic cancer	0.0131	0.0212	CbGbCtD
Citalopram—CYP3A4—Irinotecan—pancreatic cancer	0.0118	0.0192	CbGbCtD
Citalopram—ABCB1—Doxorubicin—pancreatic cancer	0.0108	0.0175	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—pancreatic cancer	0.0101	0.0165	CbGbCtD
Citalopram—CYP3A4—Docetaxel—pancreatic cancer	0.00865	0.014	CbGbCtD
Citalopram—CYP3A4—Sunitinib—pancreatic cancer	0.00861	0.014	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—pancreatic cancer	0.00645	0.0105	CbGbCtD
Citalopram—Hyperglycaemia—Doxorubicin—pancreatic cancer	7.65e-05	0.000236	CcSEcCtD
Citalopram—Diarrhoea—Irinotecan—pancreatic cancer	7.65e-05	0.000236	CcSEcCtD
Citalopram—Agranulocytosis—Epirubicin—pancreatic cancer	7.63e-05	0.000235	CcSEcCtD
Citalopram—Pneumonia—Doxorubicin—pancreatic cancer	7.61e-05	0.000234	CcSEcCtD
Citalopram—Shock—Docetaxel—pancreatic cancer	7.61e-05	0.000234	CcSEcCtD
Citalopram—Nervous system disorder—Docetaxel—pancreatic cancer	7.58e-05	0.000234	CcSEcCtD
Citalopram—Pruritus—Fluorouracil—pancreatic cancer	7.58e-05	0.000234	CcSEcCtD
Citalopram—Thrombocytopenia—Docetaxel—pancreatic cancer	7.57e-05	0.000233	CcSEcCtD
Citalopram—Infestation—Doxorubicin—pancreatic cancer	7.56e-05	0.000233	CcSEcCtD
Citalopram—Infestation NOS—Doxorubicin—pancreatic cancer	7.56e-05	0.000233	CcSEcCtD
Citalopram—Tachycardia—Docetaxel—pancreatic cancer	7.54e-05	0.000233	CcSEcCtD
Citalopram—Skin disorder—Docetaxel—pancreatic cancer	7.51e-05	0.000231	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	7.5e-05	0.000231	CcSEcCtD
Citalopram—Bradycardia—Epirubicin—pancreatic cancer	7.47e-05	0.00023	CcSEcCtD
Citalopram—Diarrhoea—Gemcitabine—pancreatic cancer	7.45e-05	0.00023	CcSEcCtD
Citalopram—Neuropathy peripheral—Doxorubicin—pancreatic cancer	7.41e-05	0.000229	CcSEcCtD
Citalopram—Dizziness—Irinotecan—pancreatic cancer	7.39e-05	0.000228	CcSEcCtD
Citalopram—Haemoglobin—Epirubicin—pancreatic cancer	7.38e-05	0.000227	CcSEcCtD
Citalopram—Stomatitis—Doxorubicin—pancreatic cancer	7.37e-05	0.000227	CcSEcCtD
Citalopram—Jaundice—Doxorubicin—pancreatic cancer	7.37e-05	0.000227	CcSEcCtD
Citalopram—Anorexia—Docetaxel—pancreatic cancer	7.37e-05	0.000227	CcSEcCtD
Citalopram—Rhinitis—Epirubicin—pancreatic cancer	7.36e-05	0.000227	CcSEcCtD
Citalopram—Conjunctivitis—Doxorubicin—pancreatic cancer	7.35e-05	0.000227	CcSEcCtD
Citalopram—Urinary tract infection—Doxorubicin—pancreatic cancer	7.35e-05	0.000227	CcSEcCtD
Citalopram—Haemorrhage—Epirubicin—pancreatic cancer	7.34e-05	0.000226	CcSEcCtD
Citalopram—Hepatitis—Epirubicin—pancreatic cancer	7.34e-05	0.000226	CcSEcCtD
Citalopram—Diarrhoea—Fluorouracil—pancreatic cancer	7.33e-05	0.000226	CcSEcCtD
Citalopram—Hypoaesthesia—Epirubicin—pancreatic cancer	7.3e-05	0.000225	CcSEcCtD
Citalopram—Pharyngitis—Epirubicin—pancreatic cancer	7.28e-05	0.000224	CcSEcCtD
Citalopram—Sweating—Doxorubicin—pancreatic cancer	7.25e-05	0.000224	CcSEcCtD
Citalopram—Urinary tract disorder—Epirubicin—pancreatic cancer	7.25e-05	0.000223	CcSEcCtD
Citalopram—Oedema peripheral—Epirubicin—pancreatic cancer	7.23e-05	0.000223	CcSEcCtD
Citalopram—Hypotension—Docetaxel—pancreatic cancer	7.22e-05	0.000223	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—pancreatic cancer	7.21e-05	0.000222	CcSEcCtD
Citalopram—Connective tissue disorder—Epirubicin—pancreatic cancer	7.21e-05	0.000222	CcSEcCtD
Citalopram—Urethral disorder—Epirubicin—pancreatic cancer	7.19e-05	0.000222	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—pancreatic cancer	7.15e-05	0.00022	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—pancreatic cancer	7.13e-05	0.00022	CcSEcCtD
Citalopram—Vomiting—Irinotecan—pancreatic cancer	7.11e-05	0.000219	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—pancreatic cancer	7.1e-05	0.000219	CcSEcCtD
Citalopram—Dizziness—Fluorouracil—pancreatic cancer	7.08e-05	0.000218	CcSEcCtD
Citalopram—Visual impairment—Epirubicin—pancreatic cancer	7.07e-05	0.000218	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—pancreatic cancer	7.06e-05	0.000218	CcSEcCtD
Citalopram—Rash—Irinotecan—pancreatic cancer	7.05e-05	0.000217	CcSEcCtD
Citalopram—Dermatitis—Irinotecan—pancreatic cancer	7.04e-05	0.000217	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	7.04e-05	0.000217	CcSEcCtD
Citalopram—Headache—Irinotecan—pancreatic cancer	7.01e-05	0.000216	CcSEcCtD
Citalopram—Insomnia—Docetaxel—pancreatic cancer	6.99e-05	0.000215	CcSEcCtD
Citalopram—Paraesthesia—Docetaxel—pancreatic cancer	6.94e-05	0.000214	CcSEcCtD
Citalopram—Erythema multiforme—Epirubicin—pancreatic cancer	6.94e-05	0.000214	CcSEcCtD
Citalopram—Vomiting—Gemcitabine—pancreatic cancer	6.93e-05	0.000213	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—pancreatic cancer	6.91e-05	0.000213	CcSEcCtD
Citalopram—Dyspnoea—Docetaxel—pancreatic cancer	6.89e-05	0.000212	CcSEcCtD
Citalopram—Somnolence—Docetaxel—pancreatic cancer	6.87e-05	0.000212	CcSEcCtD
Citalopram—Rash—Gemcitabine—pancreatic cancer	6.87e-05	0.000212	CcSEcCtD
Citalopram—Dermatitis—Gemcitabine—pancreatic cancer	6.86e-05	0.000211	CcSEcCtD
Citalopram—Eye disorder—Epirubicin—pancreatic cancer	6.86e-05	0.000211	CcSEcCtD
Citalopram—Tinnitus—Epirubicin—pancreatic cancer	6.84e-05	0.000211	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—pancreatic cancer	6.82e-05	0.00021	CcSEcCtD
Citalopram—Headache—Gemcitabine—pancreatic cancer	6.82e-05	0.00021	CcSEcCtD
Citalopram—Flushing—Epirubicin—pancreatic cancer	6.81e-05	0.00021	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—pancreatic cancer	6.81e-05	0.00021	CcSEcCtD
Citalopram—Vomiting—Fluorouracil—pancreatic cancer	6.81e-05	0.00021	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—pancreatic cancer	6.81e-05	0.00021	CcSEcCtD
Citalopram—Dyspepsia—Docetaxel—pancreatic cancer	6.8e-05	0.00021	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—pancreatic cancer	6.79e-05	0.000209	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—pancreatic cancer	6.79e-05	0.000209	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—pancreatic cancer	6.76e-05	0.000208	CcSEcCtD
Citalopram—Rash—Fluorouracil—pancreatic cancer	6.75e-05	0.000208	CcSEcCtD
Citalopram—Dermatitis—Fluorouracil—pancreatic cancer	6.75e-05	0.000208	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—pancreatic cancer	6.74e-05	0.000208	CcSEcCtD
Citalopram—Decreased appetite—Docetaxel—pancreatic cancer	6.72e-05	0.000207	CcSEcCtD
Citalopram—Headache—Fluorouracil—pancreatic cancer	6.71e-05	0.000207	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—pancreatic cancer	6.71e-05	0.000207	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—pancreatic cancer	6.69e-05	0.000206	CcSEcCtD
Citalopram—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6.67e-05	0.000206	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—pancreatic cancer	6.67e-05	0.000206	CcSEcCtD
Citalopram—Fatigue—Docetaxel—pancreatic cancer	6.66e-05	0.000205	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—pancreatic cancer	6.66e-05	0.000205	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—pancreatic cancer	6.66e-05	0.000205	CcSEcCtD
Citalopram—Nausea—Irinotecan—pancreatic cancer	6.64e-05	0.000205	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—pancreatic cancer	6.63e-05	0.000204	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—pancreatic cancer	6.61e-05	0.000204	CcSEcCtD
Citalopram—Pain—Docetaxel—pancreatic cancer	6.61e-05	0.000204	CcSEcCtD
Citalopram—Constipation—Docetaxel—pancreatic cancer	6.61e-05	0.000204	CcSEcCtD
Citalopram—Chills—Epirubicin—pancreatic cancer	6.58e-05	0.000203	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—pancreatic cancer	6.56e-05	0.000202	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—pancreatic cancer	6.54e-05	0.000202	CcSEcCtD
Citalopram—Alopecia—Epirubicin—pancreatic cancer	6.48e-05	0.0002	CcSEcCtD
Citalopram—Nausea—Gemcitabine—pancreatic cancer	6.47e-05	0.000199	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—pancreatic cancer	6.43e-05	0.000198	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—pancreatic cancer	6.42e-05	0.000198	CcSEcCtD
Citalopram—Erythema—Epirubicin—pancreatic cancer	6.39e-05	0.000197	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—pancreatic cancer	6.39e-05	0.000197	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—pancreatic cancer	6.37e-05	0.000196	CcSEcCtD
Citalopram—Nausea—Fluorouracil—pancreatic cancer	6.36e-05	0.000196	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—pancreatic cancer	6.35e-05	0.000196	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—pancreatic cancer	6.33e-05	0.000195	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.32e-05	0.000195	CcSEcCtD
Citalopram—Flushing—Doxorubicin—pancreatic cancer	6.3e-05	0.000194	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—pancreatic cancer	6.3e-05	0.000194	CcSEcCtD
Citalopram—Flatulence—Epirubicin—pancreatic cancer	6.3e-05	0.000194	CcSEcCtD
Citalopram—Tension—Epirubicin—pancreatic cancer	6.27e-05	0.000193	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—pancreatic cancer	6.26e-05	0.000193	CcSEcCtD
Citalopram—Nervousness—Epirubicin—pancreatic cancer	6.2e-05	0.000191	CcSEcCtD
Citalopram—Back pain—Epirubicin—pancreatic cancer	6.18e-05	0.00019	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—pancreatic cancer	6.16e-05	0.00019	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—pancreatic cancer	6.14e-05	0.000189	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—pancreatic cancer	6.13e-05	0.000189	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—pancreatic cancer	6.12e-05	0.000189	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—pancreatic cancer	6.11e-05	0.000188	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—pancreatic cancer	6.11e-05	0.000188	CcSEcCtD
Citalopram—Chills—Doxorubicin—pancreatic cancer	6.09e-05	0.000188	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—pancreatic cancer	6.07e-05	0.000187	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—pancreatic cancer	6.02e-05	0.000186	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—pancreatic cancer	6e-05	0.000185	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—pancreatic cancer	5.95e-05	0.000183	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—pancreatic cancer	5.93e-05	0.000183	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—pancreatic cancer	5.91e-05	0.000182	CcSEcCtD
Citalopram—Erythema—Doxorubicin—pancreatic cancer	5.91e-05	0.000182	CcSEcCtD
Citalopram—Anaemia—Epirubicin—pancreatic cancer	5.9e-05	0.000182	CcSEcCtD
Citalopram—Agitation—Epirubicin—pancreatic cancer	5.87e-05	0.000181	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—pancreatic cancer	5.82e-05	0.00018	CcSEcCtD
Citalopram—Tension—Doxorubicin—pancreatic cancer	5.8e-05	0.000179	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—pancreatic cancer	5.79e-05	0.000178	CcSEcCtD
Citalopram—Malaise—Epirubicin—pancreatic cancer	5.76e-05	0.000178	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—pancreatic cancer	5.74e-05	0.000177	CcSEcCtD
Citalopram—Vertigo—Epirubicin—pancreatic cancer	5.74e-05	0.000177	CcSEcCtD
Citalopram—Syncope—Epirubicin—pancreatic cancer	5.73e-05	0.000177	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—pancreatic cancer	5.72e-05	0.000176	CcSEcCtD
Citalopram—Back pain—Doxorubicin—pancreatic cancer	5.72e-05	0.000176	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—pancreatic cancer	5.7e-05	0.000176	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—pancreatic cancer	5.68e-05	0.000175	CcSEcCtD
Citalopram—Palpitations—Epirubicin—pancreatic cancer	5.65e-05	0.000174	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—pancreatic cancer	5.61e-05	0.000173	CcSEcCtD
Citalopram—Cough—Epirubicin—pancreatic cancer	5.57e-05	0.000172	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—pancreatic cancer	5.57e-05	0.000172	CcSEcCtD
Citalopram—Asthenia—Docetaxel—pancreatic cancer	5.55e-05	0.000171	CcSEcCtD
Citalopram—Convulsion—Epirubicin—pancreatic cancer	5.54e-05	0.000171	CcSEcCtD
Citalopram—Hypertension—Epirubicin—pancreatic cancer	5.52e-05	0.00017	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.48e-05	0.000169	CcSEcCtD
Citalopram—Pruritus—Docetaxel—pancreatic cancer	5.47e-05	0.000169	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—pancreatic cancer	5.46e-05	0.000168	CcSEcCtD
Citalopram—Chest pain—Epirubicin—pancreatic cancer	5.44e-05	0.000168	CcSEcCtD
Citalopram—Myalgia—Epirubicin—pancreatic cancer	5.44e-05	0.000168	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—pancreatic cancer	5.44e-05	0.000168	CcSEcCtD
Citalopram—Agitation—Doxorubicin—pancreatic cancer	5.43e-05	0.000167	CcSEcCtD
Citalopram—Anxiety—Epirubicin—pancreatic cancer	5.42e-05	0.000167	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	5.4e-05	0.000166	CcSEcCtD
Citalopram—Discomfort—Epirubicin—pancreatic cancer	5.37e-05	0.000166	CcSEcCtD
Citalopram—Malaise—Doxorubicin—pancreatic cancer	5.33e-05	0.000164	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—pancreatic cancer	5.32e-05	0.000164	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—pancreatic cancer	5.31e-05	0.000164	CcSEcCtD
Citalopram—Syncope—Doxorubicin—pancreatic cancer	5.3e-05	0.000163	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—pancreatic cancer	5.29e-05	0.000163	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—pancreatic cancer	5.29e-05	0.000163	CcSEcCtD
Citalopram—Confusional state—Epirubicin—pancreatic cancer	5.26e-05	0.000162	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—pancreatic cancer	5.22e-05	0.000161	CcSEcCtD
Citalopram—Oedema—Epirubicin—pancreatic cancer	5.21e-05	0.000161	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—pancreatic cancer	5.21e-05	0.000161	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—pancreatic cancer	5.2e-05	0.00016	CcSEcCtD
Citalopram—Infection—Epirubicin—pancreatic cancer	5.18e-05	0.00016	CcSEcCtD
Citalopram—Cough—Doxorubicin—pancreatic cancer	5.16e-05	0.000159	CcSEcCtD
Citalopram—Shock—Epirubicin—pancreatic cancer	5.13e-05	0.000158	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—pancreatic cancer	5.12e-05	0.000158	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—pancreatic cancer	5.11e-05	0.000158	CcSEcCtD
Citalopram—Dizziness—Docetaxel—pancreatic cancer	5.11e-05	0.000158	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—pancreatic cancer	5.1e-05	0.000157	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—pancreatic cancer	5.1e-05	0.000157	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—pancreatic cancer	5.09e-05	0.000157	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—pancreatic cancer	5.06e-05	0.000156	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—pancreatic cancer	5.04e-05	0.000155	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—pancreatic cancer	5.03e-05	0.000155	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—pancreatic cancer	5.03e-05	0.000155	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—pancreatic cancer	5.03e-05	0.000155	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—pancreatic cancer	5.02e-05	0.000155	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5e-05	0.000154	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—pancreatic cancer	4.97e-05	0.000153	CcSEcCtD
Citalopram—Anorexia—Epirubicin—pancreatic cancer	4.97e-05	0.000153	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—pancreatic cancer	4.92e-05	0.000152	CcSEcCtD
Citalopram—Vomiting—Docetaxel—pancreatic cancer	4.91e-05	0.000151	CcSEcCtD
Citalopram—Rash—Docetaxel—pancreatic cancer	4.87e-05	0.00015	CcSEcCtD
Citalopram—Hypotension—Epirubicin—pancreatic cancer	4.87e-05	0.00015	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—pancreatic cancer	4.87e-05	0.00015	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—pancreatic cancer	4.86e-05	0.00015	CcSEcCtD
Citalopram—Headache—Docetaxel—pancreatic cancer	4.84e-05	0.000149	CcSEcCtD
Citalopram—Oedema—Doxorubicin—pancreatic cancer	4.82e-05	0.000149	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.82e-05	0.000149	CcSEcCtD
Citalopram—Infection—Doxorubicin—pancreatic cancer	4.79e-05	0.000148	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.75e-05	0.000146	CcSEcCtD
Citalopram—Shock—Doxorubicin—pancreatic cancer	4.75e-05	0.000146	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—pancreatic cancer	4.73e-05	0.000146	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.72e-05	0.000146	CcSEcCtD
Citalopram—Insomnia—Epirubicin—pancreatic cancer	4.72e-05	0.000145	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—pancreatic cancer	4.71e-05	0.000145	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—pancreatic cancer	4.69e-05	0.000144	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—pancreatic cancer	4.68e-05	0.000144	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.66e-05	0.000144	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—pancreatic cancer	4.65e-05	0.000143	CcSEcCtD
Citalopram—Somnolence—Epirubicin—pancreatic cancer	4.64e-05	0.000143	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—pancreatic cancer	4.6e-05	0.000142	CcSEcCtD
Citalopram—Nausea—Docetaxel—pancreatic cancer	4.59e-05	0.000142	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—pancreatic cancer	4.59e-05	0.000141	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—pancreatic cancer	4.53e-05	0.00014	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—pancreatic cancer	4.51e-05	0.000139	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.5e-05	0.000139	CcSEcCtD
Citalopram—Fatigue—Epirubicin—pancreatic cancer	4.5e-05	0.000139	CcSEcCtD
Citalopram—Constipation—Epirubicin—pancreatic cancer	4.46e-05	0.000137	CcSEcCtD
Citalopram—Pain—Epirubicin—pancreatic cancer	4.46e-05	0.000137	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.4e-05	0.000135	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—pancreatic cancer	4.36e-05	0.000134	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—pancreatic cancer	4.33e-05	0.000134	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—pancreatic cancer	4.3e-05	0.000133	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—pancreatic cancer	4.3e-05	0.000132	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—pancreatic cancer	4.29e-05	0.000132	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.26e-05	0.000131	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—pancreatic cancer	4.25e-05	0.000131	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—pancreatic cancer	4.19e-05	0.000129	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.16e-05	0.000128	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—pancreatic cancer	4.16e-05	0.000128	CcSEcCtD
Citalopram—Urticaria—Epirubicin—pancreatic cancer	4.14e-05	0.000128	CcSEcCtD
Citalopram—Constipation—Doxorubicin—pancreatic cancer	4.13e-05	0.000127	CcSEcCtD
Citalopram—Pain—Doxorubicin—pancreatic cancer	4.13e-05	0.000127	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—pancreatic cancer	4.12e-05	0.000127	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—pancreatic cancer	4.12e-05	0.000127	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—pancreatic cancer	3.98e-05	0.000123	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.94e-05	0.000122	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—pancreatic cancer	3.84e-05	0.000118	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—pancreatic cancer	3.83e-05	0.000118	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—pancreatic cancer	3.81e-05	0.000118	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—pancreatic cancer	3.81e-05	0.000118	CcSEcCtD
Citalopram—Asthenia—Epirubicin—pancreatic cancer	3.74e-05	0.000115	CcSEcCtD
Citalopram—Pruritus—Epirubicin—pancreatic cancer	3.69e-05	0.000114	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—pancreatic cancer	3.57e-05	0.00011	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—pancreatic cancer	3.55e-05	0.00011	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—pancreatic cancer	3.46e-05	0.000107	CcSEcCtD
Citalopram—Dizziness—Epirubicin—pancreatic cancer	3.45e-05	0.000106	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—pancreatic cancer	3.41e-05	0.000105	CcSEcCtD
Citalopram—Vomiting—Epirubicin—pancreatic cancer	3.32e-05	0.000102	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—pancreatic cancer	3.3e-05	0.000102	CcSEcCtD
Citalopram—Rash—Epirubicin—pancreatic cancer	3.29e-05	0.000101	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—pancreatic cancer	3.28e-05	0.000101	CcSEcCtD
Citalopram—Headache—Epirubicin—pancreatic cancer	3.27e-05	0.000101	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—pancreatic cancer	3.19e-05	9.83e-05	CcSEcCtD
Citalopram—Nausea—Epirubicin—pancreatic cancer	3.1e-05	9.55e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—pancreatic cancer	3.07e-05	9.45e-05	CcSEcCtD
Citalopram—Rash—Doxorubicin—pancreatic cancer	3.04e-05	9.38e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—pancreatic cancer	3.04e-05	9.37e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—pancreatic cancer	3.02e-05	9.32e-05	CcSEcCtD
Citalopram—Nausea—Doxorubicin—pancreatic cancer	2.87e-05	8.83e-05	CcSEcCtD
Citalopram—ADRA1A—GPCR downstream signaling—CXCL8—pancreatic cancer	1.05e-05	0.000178	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HES1—pancreatic cancer	1.04e-05	0.000175	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.04e-05	0.000175	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CD44—pancreatic cancer	1.03e-05	0.000175	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.03e-05	0.000174	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	1.02e-05	0.000173	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	1.02e-05	0.000172	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.02e-05	0.000172	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GCG—pancreatic cancer	1.02e-05	0.000172	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.01e-05	0.000171	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.01e-05	0.000171	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APOE—pancreatic cancer	9.98e-06	0.000169	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CB—pancreatic cancer	9.93e-06	0.000168	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GCG—pancreatic cancer	9.91e-06	0.000168	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KDR—pancreatic cancer	9.77e-06	0.000165	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CD44—pancreatic cancer	9.74e-06	0.000165	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CXCL8—pancreatic cancer	9.72e-06	0.000165	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	9.69e-06	0.000164	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—STK11—pancreatic cancer	9.55e-06	0.000162	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CXCL8—pancreatic cancer	9.54e-06	0.000161	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GCG—pancreatic cancer	9.34e-06	0.000158	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—STK11—pancreatic cancer	9.32e-06	0.000158	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	9.3e-06	0.000157	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.27e-06	0.000157	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TERT—pancreatic cancer	9.26e-06	0.000157	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TERT—pancreatic cancer	9.23e-06	0.000156	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	9.21e-06	0.000156	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TERT—pancreatic cancer	9.09e-06	0.000154	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	9e-06	0.000152	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	9e-06	0.000152	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.96e-06	0.000152	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGF—pancreatic cancer	8.9e-06	0.000151	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HIF1A—pancreatic cancer	8.86e-06	0.00015	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—APOE—pancreatic cancer	8.84e-06	0.00015	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TSC2—pancreatic cancer	8.83e-06	0.000149	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	8.83e-06	0.000149	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GLP1R—pancreatic cancer	8.81e-06	0.000149	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	8.81e-06	0.000149	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—STK11—pancreatic cancer	8.78e-06	0.000149	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	8.69e-06	0.000147	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	8.67e-06	0.000147	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—DPYD—pancreatic cancer	8.67e-06	0.000147	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—APOE—pancreatic cancer	8.66e-06	0.000146	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APOE—pancreatic cancer	8.64e-06	0.000146	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APOE—pancreatic cancer	8.62e-06	0.000146	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	8.48e-06	0.000144	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KDR—pancreatic cancer	8.47e-06	0.000143	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KDR—pancreatic cancer	8.44e-06	0.000143	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	8.31e-06	0.000141	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CD44—pancreatic cancer	8.25e-06	0.00014	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	8.22e-06	0.000139	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—TYMS—pancreatic cancer	8.21e-06	0.000139	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	8.2e-06	0.000139	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.08e-06	0.000137	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NFKBIA—pancreatic cancer	8.06e-06	0.000136	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	8.03e-06	0.000136	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—TYMS—pancreatic cancer	8.01e-06	0.000136	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.01e-06	0.000135	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOTCH1—pancreatic cancer	7.98e-06	0.000135	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	7.98e-06	0.000135	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	7.95e-06	0.000135	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	7.91e-06	0.000134	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GCG—pancreatic cancer	7.91e-06	0.000134	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	7.9e-06	0.000134	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.84e-06	0.000133	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	7.83e-06	0.000132	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CG—pancreatic cancer	7.81e-06	0.000132	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CG—pancreatic cancer	7.8e-06	0.000132	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—NRAS—pancreatic cancer	7.8e-06	0.000132	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	7.78e-06	0.000132	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	7.78e-06	0.000132	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	7.75e-06	0.000131	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGF—pancreatic cancer	7.71e-06	0.00013	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—pancreatic cancer	7.7e-06	0.00013	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGF—pancreatic cancer	7.69e-06	0.00013	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	7.66e-06	0.00013	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	7.66e-06	0.00013	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	7.57e-06	0.000128	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TYMS—pancreatic cancer	7.55e-06	0.000128	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—pancreatic cancer	7.54e-06	0.000128	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—STK11—pancreatic cancer	7.44e-06	0.000126	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	7.12e-06	0.00012	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	7.11e-06	0.00012	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	7.08e-06	0.00012	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	7.01e-06	0.000119	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.98e-06	0.000118	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	6.97e-06	0.000118	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	6.9e-06	0.000117	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—pancreatic cancer	6.87e-06	0.000116	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	6.86e-06	0.000116	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	6.84e-06	0.000116	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.79e-06	0.000115	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.77e-06	0.000115	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	6.73e-06	0.000114	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	6.71e-06	0.000114	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	6.69e-06	0.000113	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOE—pancreatic cancer	6.68e-06	0.000113	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.67e-06	0.000113	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	6.63e-06	0.000112	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	6.59e-06	0.000111	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	6.59e-06	0.000111	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOE—pancreatic cancer	6.52e-06	0.00011	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	6.4e-06	0.000108	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—pancreatic cancer	6.4e-06	0.000108	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CD44—pancreatic cancer	6.37e-06	0.000108	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	6.35e-06	0.000107	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.32e-06	0.000107	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	6.18e-06	0.000105	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.17e-06	0.000104	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.15e-06	0.000104	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOE—pancreatic cancer	6.14e-06	0.000104	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	6.12e-06	0.000103	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	6.11e-06	0.000103	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GCG—pancreatic cancer	6.11e-06	0.000103	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—pancreatic cancer	6.06e-06	0.000102	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.05e-06	0.000102	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	6.03e-06	0.000102	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	6e-06	0.000101	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	5.99e-06	0.000101	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	5.98e-06	0.000101	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	5.96e-06	0.000101	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	5.96e-06	0.000101	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—pancreatic cancer	5.93e-06	0.0001	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.88e-06	9.95e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	5.87e-06	9.93e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—pancreatic cancer	5.82e-06	9.84e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	5.82e-06	9.84e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	5.74e-06	9.72e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—STK11—pancreatic cancer	5.74e-06	9.71e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	5.73e-06	9.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	5.71e-06	9.66e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	5.69e-06	9.63e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—pancreatic cancer	5.68e-06	9.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	5.64e-06	9.54e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	5.6e-06	9.48e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	5.55e-06	9.39e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	5.54e-06	9.38e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	5.53e-06	9.36e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SRC—pancreatic cancer	5.53e-06	9.35e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—pancreatic cancer	5.5e-06	9.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	5.48e-06	9.27e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	5.45e-06	9.21e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	5.4e-06	9.13e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	5.38e-06	9.11e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—pancreatic cancer	5.35e-06	9.06e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.35e-06	9.05e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	5.33e-06	9.03e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	5.33e-06	9.02e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	5.32e-06	9e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	5.3e-06	8.97e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	5.3e-06	8.96e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	5.28e-06	8.94e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—pancreatic cancer	5.28e-06	8.93e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	5.25e-06	8.89e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOE—pancreatic cancer	5.2e-06	8.8e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	5.2e-06	8.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—pancreatic cancer	5.2e-06	8.79e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	5.18e-06	8.76e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—pancreatic cancer	5.17e-06	8.75e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.17e-06	8.75e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—pancreatic cancer	5.17e-06	8.74e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	5.15e-06	8.71e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	5.1e-06	8.63e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	5.07e-06	8.58e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	5.04e-06	8.53e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	5.02e-06	8.5e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—pancreatic cancer	4.95e-06	8.38e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	4.95e-06	8.37e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	4.94e-06	8.36e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.94e-06	8.35e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.93e-06	8.33e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.87e-06	8.24e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	4.85e-06	8.2e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SRC—pancreatic cancer	4.79e-06	8.11e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SRC—pancreatic cancer	4.78e-06	8.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	4.7e-06	7.95e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.7e-06	7.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	4.67e-06	7.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	4.65e-06	7.87e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—pancreatic cancer	4.62e-06	7.82e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	4.62e-06	7.81e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NRAS—pancreatic cancer	4.61e-06	7.8e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	4.6e-06	7.79e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	4.59e-06	7.77e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	4.58e-06	7.75e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	4.58e-06	7.75e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—pancreatic cancer	4.58e-06	7.74e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	4.53e-06	7.67e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.53e-06	7.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	4.52e-06	7.65e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.51e-06	7.63e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.47e-06	7.56e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—pancreatic cancer	4.29e-06	7.26e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	4.28e-06	7.25e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—pancreatic cancer	4.28e-06	7.24e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	4.27e-06	7.22e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.25e-06	7.19e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	4.21e-06	7.13e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.21e-06	7.12e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	4.21e-06	7.12e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	4.2e-06	7.11e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—pancreatic cancer	4.2e-06	7.1e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	4.19e-06	7.08e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.13e-06	6.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	4.12e-06	6.97e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—pancreatic cancer	4.07e-06	6.88e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOE—pancreatic cancer	4.02e-06	6.79e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.99e-06	6.75e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—pancreatic cancer	3.97e-06	6.71e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	3.95e-06	6.69e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—pancreatic cancer	3.89e-06	6.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	3.89e-06	6.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.89e-06	6.58e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	3.73e-06	6.3e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.67e-06	6.21e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	3.65e-06	6.17e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	3.64e-06	6.17e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	3.63e-06	6.15e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.62e-06	6.13e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.6e-06	6.09e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.58e-06	6.05e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.57e-06	6.03e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—pancreatic cancer	3.53e-06	5.96e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—pancreatic cancer	3.51e-06	5.95e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.5e-06	5.92e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	3.46e-06	5.85e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	3.44e-06	5.81e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—pancreatic cancer	3.37e-06	5.7e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	3.36e-06	5.69e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	3.31e-06	5.6e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.19e-06	5.39e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.11e-06	5.26e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—pancreatic cancer	3.04e-06	5.15e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—pancreatic cancer	2.98e-06	5.04e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—pancreatic cancer	2.98e-06	5.04e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	2.97e-06	5.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	2.92e-06	4.94e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.82e-06	4.76e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.78e-06	4.7e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.75e-06	4.66e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.75e-06	4.65e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.59e-06	4.38e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.4e-06	4.06e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—pancreatic cancer	2.3e-06	3.89e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—pancreatic cancer	2.24e-06	3.8e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.19e-06	3.71e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.12e-06	3.58e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.79e-06	3.03e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.69e-06	2.86e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.38e-06	2.34e-05	CbGpPWpGaD
